Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma research hub

A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases

This study looks at new ways to treat advanced melanoma, a type of skin cancer. It combines a standard cancer drug, pembrolizumab, with injections directly into the cancer. Researchers want to see if these new combinations can shrink tumours in people whose cancer hasn’t responded well to previous treatments.